China Rapid Finance Ltd - ADR  

(Public, NYSE:XRF)   Watch this stock  
Find more results for XRF
9.43
+0.20 (2.17%)
After Hours: 9.43 0.00 (0.00%)
Nov 21, 5:57PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 7.29 - 9.60
52 week 5.60 - 12.86
Open 7.97
Vol / Avg. 1.06M/611,054.00
Mkt cap 613.76M
P/E     -
Div/yield     -
EPS     -
Shares 65.09M
Beta     -
Inst. own 14%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -89.21% -59.73%
Operating margin -90.01% -60.19%
EBITD margin - -57.24%
Return on average assets -59.64% -52.65%
Return on average equity - -
Employees 3,119 -
CDP Score - -

Address

5Th Floor, Building D, Benq Plaza, 207 Songhong Road, Changning District
SHANGHAI, SHA 200335
China
+86-21-26826830 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

China Rapid Finance Limited is a consumer lending company. The Company, through its subsidiaries, is principally engaged in providing a consumer lending marketplace for lenders and borrowers in the People’s Republic of China with predictive selection technology (PST), automated decisioning technology (ADT), and non-credit data analytic and risk-based pricing capabilities. Its target market includes prime and near-prime Emerging Middle-class, Mobile Active consumers (EMMAs). It serves marketplace investors and borrowers both online and through a physical network of over one hundred data verification centers. It offers consumption loans, lifestyle loans and micro-credit lending. The Company generates revenue primarily from transaction and service fees by providing lending-related services. As of March 31, 2017, the Company had facilitated more than 10.7 million loans to more than 1.4 million borrowers.

Officers and directors

Zane Wang Chief Executive Officer
Bio & Compensation  - Reuters
Steven Li Chief Technology Officer
Bio & Compensation  - Reuters
Alvin Yu Vice President, Marketing
Bio & Compensation  - Reuters
Ray Liu Vice President
Bio & Compensation  - Reuters